Table 4.

Completing Vaccination After PEG3350 Challenge

PEG-challenged patients	All patients challenged	Developed symptoms during PEG challenge	No symptoms during PEG challenge
Total number of PEG-challenged patients	23	10/23 (43.5)	13/23 (56.5)
Tolerated second mRNA vaccine	20/23 (87.0)	8/10 (80.0)	12/13 (92.3)
Patient chose to receive J&J	1/23 (4.3)	0	1/13 (7.7)
Lost to follow-up	2/23 (8.7)	2/10 (20.0)	0

Data are presented as number (percentage).

Abbreviations: COVID-19, coronavirus disease 2019; J&J, Johnson & Johnson COVID-19 vaccine; mRNA, messenger RNA; PEG, polyethylene glycol